Conexeu Sciences Inc. Common Stock

Conexeu Sciences is developing tissue-regeneration technology to address large-volume tissue restoration needs driven by widespread GLP-1 weight-loss drug use. CEO Miles Harrison discussed in an IPO Edge fireside chat how the company's single bioresorbable regenerative scaffold platform aims to serve multiple markets including wound care, aesthetics, oral health, veterinary medicine, and reconstruction. The company plans to submit a 510(k) application to the FDA in early 2027 for its initial indication, with additional catalysts including data publications, breast program progress, and expansion into dental and veterinary markets. Conexeu's technology is positioned as a potential alternative to silicone breast implants and targets areas where current fillers and injectables fall short.

Conexeu Sciences is advancing its investigational CXU™ tissue-restoration platform into medical aesthetics, targeting large-volume body contouring and restoration of the breasts, hips, and buttocks. The company has completed its 12-month P.R.O.O.F. preclinical study, which evaluated CXU™ in a large-volume model, restoring roughly 200cc, close to a full cup size. Conexeu aims to establish a new category called bioregeneration, pairing meaningful volume restoration with tissue regeneration, and plans a 510(k) submission in the first quarter of 2027. The breast implant market is projected to grow from $2.21 billion to $3.21 billion by 2030, while the buttock augmentation market is expected to expand from $2.99 billion in 2023 to $11.72 billion by 2030. GLP-1 adoption is driving demand, with the related aesthetics opportunity projected to nearly triple from roughly $0.7 billion to $2.0 billion by 2030.

Conexeu Sciences has opened a new research and development facility at adMare BioInnovations’ M4 Innovation Centre in Vancouver, expanding the operational base for its CXU regenerative tissue platform. The company, which is preclinical-stage, is designing the single-technology platform to scale across soft-tissue restoration markets, with aesthetics and body contouring increasingly at the center of its direction. The facility will support advancement of the CXU platform and its lead device candidate, Ten-Minute Tissue, a thermosensitive material designed to be injected as a liquid and set into a stable gel at body temperature. Conexeu is targeting the aesthetics opportunity created by GLP-1 therapies, a market it estimates is heading toward roughly $2 billion by 2030, and anticipates a 510(k) submission in wound care in early 2027. The same platform also extends to wound care, periodontal applications, and a 3D-bioprinted breast matrix program called B.R.E.A.S.T.

Conexeu Sciences has opened a new research and development facility at adMare BioInnovations' M4 Innovation Centre in Vancouver, Canada. The company commemorated the milestone with a ribbon-cutting ceremony on June 23. Conexeu is among the first companies operating within the 30,000-square-foot centre, which provides specialized laboratory infrastructure and shared scientific resources. The new laboratory will serve as the centre of Conexeu's ongoing research, product development, and commercialization efforts, including advancement of its proprietary CXU regenerative tissue platform and B.R.E.A.S.T., a novel 3D-bioprinted breast matrix designed to help the body regenerate natural tissue following mastectomy.

The regenerative medicine market is projected to surpass US$100 billion within roughly a decade, driven by a shift from tissue replacement to regeneration using biomaterials, cell therapies, and 3D bioprinting. Independent estimates place the broad market in the tens of billions of dollars in 2026, with compound annual growth rates frequently estimated in the high teens to mid-20s percent. Key drivers include aging populations, the diabetes epidemic, rising surgical volumes, and growing demand in aesthetics, partly fueled by GLP-1 weight-loss medications. The sector spans profitable commercial leaders like Integra LifeSciences and Vericel to early-stage platform companies such as Conexeu Sciences, which began trading on Nasdaq in May 2026 with its collagen-based extracellular-matrix platform. Reimbursement policy and regulatory pathways remain critical risks, as illustrated by recent upheaval in the U.S. skin-substitute market affecting companies like Organogenesis and MiMedx.